MX2023008250A - Compuestos de derivados sustituidos en 4,6 de ip4. - Google Patents

Compuestos de derivados sustituidos en 4,6 de ip4.

Info

Publication number
MX2023008250A
MX2023008250A MX2023008250A MX2023008250A MX2023008250A MX 2023008250 A MX2023008250 A MX 2023008250A MX 2023008250 A MX2023008250 A MX 2023008250A MX 2023008250 A MX2023008250 A MX 2023008250A MX 2023008250 A MX2023008250 A MX 2023008250A
Authority
MX
Mexico
Prior art keywords
sub
alkyl
methods
derivative compounds
substituted derivative
Prior art date
Application number
MX2023008250A
Other languages
English (en)
Inventor
Bestard Joan Perelló
Roca Carolina Salcedo
Reynés Miquel David Ferrer
Ferrer María Del Mar Pérez
Mohamad Firas Bassissi
Comas Carme Serra
Ruiz Juan Lorenzo Catena
Soldevila Amadeu Llebaria
Castro Joaquín Ortega
Original Assignee
Sanifit Therapeutics S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanifit Therapeutics S A filed Critical Sanifit Therapeutics S A
Publication of MX2023008250A publication Critical patent/MX2023008250A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/093—Polyol derivatives esterified at least twice by phosphoric acid groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/117—Esters of phosphoric acids with cycloaliphatic alcohols
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/16—Esters of thiophosphoric acids or thiophosphorous acids
    • C07F9/165—Esters of thiophosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/11—Esters of phosphoric acids with hydroxyalkyl compounds without further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/65031—Five-membered rings having the nitrogen atoms in the positions 1 and 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/650952—Six-membered rings having the nitrogen atoms in the positions 1 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having three nitrogen atoms as the only ring hetero atoms
    • C07F9/6518—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms
    • C07F9/655345—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms the sulfur atom being part of a five-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona derivados sustituidos en 4,6 de IP4, sus métodos de síntesis y sus usos. En algunos aspectos, el derivado 4,6-IP4 es un compuesto de fórmula I, en donde R1, R3, R7 y R11 son OPO32-, y R5 y R9 se seleccionan del grupo que consiste en -O(Alquil)nX, -O(Alquil)yCy(Alquil2)y-Z, -O(Alquil)yA(Alquil)y-Z', y sus análogos de tiofosfato. También se proporcionan métodos, composiciones farmacéuticas y formulaciones, métodos de uso, artículos de fabricación y kits para el tratamiento de enfermedades y afecciones tales como enfermedades y afecciones relacionadas con la cristalización patológica.
MX2023008250A 2021-01-29 2022-01-31 Compuestos de derivados sustituidos en 4,6 de ip4. MX2023008250A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21382075.6A EP4036097A1 (en) 2021-01-29 2021-01-29 Ip4-4,6 substituted derivative compounds
PCT/EP2022/052164 WO2022162206A1 (en) 2021-01-29 2022-01-31 Ip4-4,6 substituted derivative compounds

Publications (1)

Publication Number Publication Date
MX2023008250A true MX2023008250A (es) 2023-07-26

Family

ID=74732816

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023008250A MX2023008250A (es) 2021-01-29 2022-01-31 Compuestos de derivados sustituidos en 4,6 de ip4.

Country Status (13)

Country Link
US (1) US20240109924A1 (es)
EP (2) EP4036097A1 (es)
JP (1) JP2024504257A (es)
KR (1) KR20230132811A (es)
CN (1) CN116745304A (es)
AR (1) AR124717A1 (es)
AU (1) AU2022212601A1 (es)
BR (1) BR112023014549A2 (es)
CA (1) CA3202780A1 (es)
IL (1) IL303825A (es)
MX (1) MX2023008250A (es)
TW (1) TW202239414A (es)
WO (1) WO2022162206A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024023359A1 (en) * 2022-07-29 2024-02-01 Sanifit Therapeutics, S.A. Ip4-4,6 substituted derivative compounds for use in the treatment, inhibition of progression, and prevention of ectopic calcification

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4755612A (en) * 1987-07-20 1988-07-05 Merck & Co., Inc. Intermediate compounds resulting from method for forming a dihydrogen-phosphate inositol
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
EP0431197A4 (en) * 1989-06-28 1991-12-04 Mitsui Toatsu Chemicals Inc. Myoinositol derivative and method of production thereof, and phosphorylating agent and its use
ATE173159T1 (de) 1992-03-25 1998-11-15 Depomed Systems Inc Auf hydroxyethylzellulose basierende oralen arzneidosisformen mit verzoegerter wirkstoffabgabe
US5582837A (en) 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
AU3290397A (en) 1996-06-10 1998-01-07 Depomed, Inc. Gastric-retentive oral controlled drug delivery system with enhanced retention properties
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
JP4083818B2 (ja) 1997-06-06 2008-04-30 ディポメド，インコーポレイティド 高度可溶性薬物の制御された放出のための胃滞留性の経口薬物投与形
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
NZ518739A (en) 1999-11-02 2004-12-24 Depomed Inc Pharmacological inducement of the fed mode for enhanced drug administration to the stomach
AU767812B2 (en) 2000-02-04 2003-11-27 Depomed, Inc. Shell-and-core dosage form approaching zero-order drug release
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
US6451808B1 (en) 2000-10-17 2002-09-17 Depomed, Inc. Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists
KR20040020056A (ko) 2001-05-29 2004-03-06 디포메드 디벨롭먼트 리미티드 위식도 역류 질환 및 야간 위산분비의 치료 방법
US20030091630A1 (en) 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
CA2464561A1 (en) 2001-10-25 2003-05-01 Depomed, Inc. Methods of treatment using a gastric retained losartan dosage
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
ES2232302B1 (es) 2003-11-07 2006-08-01 Universitat De Les Illes Balears Myo-inositol hexafosfato para uso topico.
ES2288126B2 (es) 2006-06-01 2009-07-06 Universitat De Les Illes Balears Utilizacion de fitato como agente inhibidor de la disolucion de cristales de sales calcicas para la prevencion o tratamiento de la osteoporosis.
ES2332636B1 (es) 2008-08-06 2011-02-10 Universitat De Les Illes Balears Composicion de liquido de dialisis.
EP2579036A1 (en) 2011-10-06 2013-04-10 Laboratorios Sanifit, S.L. Method for the direct detection and/or quantification of at least one compound with a molecular weight of at least 200
HUE055165T2 (hu) 2015-12-11 2021-11-29 Eth Zuerich Inozit származékok patológiás kristályosodásban való alkalmazásra
AU2016366503B2 (en) 2015-12-11 2021-02-04 ETH Zürich 4,6-di-(O-thiophosphate)-inositol-1,2,3,5-tetra-O-sulfate for C. difficile infection

Also Published As

Publication number Publication date
WO2022162206A1 (en) 2022-08-04
AU2022212601A1 (en) 2023-07-06
CA3202780A1 (en) 2022-08-04
EP4284809A1 (en) 2023-12-06
IL303825A (en) 2023-08-01
KR20230132811A (ko) 2023-09-18
AR124717A1 (es) 2023-04-26
BR112023014549A2 (pt) 2023-10-10
US20240109924A1 (en) 2024-04-04
EP4036097A1 (en) 2022-08-03
CN116745304A (zh) 2023-09-12
TW202239414A (zh) 2022-10-16
JP2024504257A (ja) 2024-01-31

Similar Documents

Publication Publication Date Title
CA2337857C (en) Calcium (3s) tetrahydro-3-furanyl(1s,2r)-3-[[(4-aminophenyl) sulfonyl](isobutyl)amino]-1-benzyl-2-(phosphonooxy)propylcarbamate
RU2500680C2 (ru) Новые замещенные пиридин-2-оны и пиридазин-3-оны
JP6031122B2 (ja) 抗微生物療法のための三環式ホウ素化合物
TW200604175A (en) Ortho substituted aryl or heteroaryl amide compounds
RS39904A (en) Nicotin-or isonicotin benzothiazole derivatives
MY140528A (en) Spiroketal derivatives and their use as therapeutic agents for diabetes
CY1110951T1 (el) Αζαϊνδολες
KR101698283B1 (ko) 티에노피리미딘 화합물의 제조 방법
EA200701035A1 (ru) Замещенные n-сульфониламинобензил-2-феноксиацетамидные соединения
CY1111980T1 (el) Παραγωγα του αμιδιου τα οποια φερουν ενα υποκαταστατο του κυκλοπροπυλαμινοκαρβονυλιου και χρησιμευουν ως αναστολεις κυτταροκινης
RU2011133128A (ru) Противоопухолевые соединения дигидропиран-2-она
AR052413A1 (es) Nuevos derivados de piridotienopiriidina
MX2023008250A (es) Compuestos de derivados sustituidos en 4,6 de ip4.
GEP20074256B (en) Novel benzothiadiazine, process for their preparation and pharmaceutical compositions containing
TW200740760A (en) Malonamide derivatives
JP3009196B2 (ja) 抗ウイルス活性を有する薬剤、燐脂質誘導体及びその製造方法
TWI268280B (en) Novel farnesyl protein transferase inhibitors as antitumor agents
MX2021000089A (es) Derivados de fenil-n-quinolina para el tratamiento de una infeccion por virus de acido ribonucleico (arn).
CA2963390C (en) Synthesis and anticancer activity of aryl and heteroaryl-quinolin derivatives
NO20080498L (no) Fluorsubstituerte 2-okso-azepanderivater
WO2019108943A1 (en) Benzene fused heterocyclic compound and use thereof
FR2854634A1 (fr) Nouveaux derives de thiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
NO20092413L (no) Pyrazolanaloger
KR101571915B1 (ko) Ｈｄａｃ 저해제로서의 술포닐피롤의 신규 제조 방법
AR055108A1 (es) Derivados de fenilpiridina, su obtencion y su utilizacion en composiciones farmaceuticas para el tratamiento del cancer.